2012558-47-1
Chemical Structure
Bulevirtide
Synonym(s): Myrcludex B
- CAS No.: 2012558-47-1
- Formula:C248H355N65O72
- Molecular Weight:5398.86
SMILES: O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(O)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N7[C@@H](CCC7)C(N[C@@H](C)C(N[C@@H](CC8=CC=CC=C8)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N9[C@@H](CCC9)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%10=CNC%11=CC=CC=C%10%11)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%12=CC=CC=C%12)C(N[C@@H](CC(N)=O)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CNC=N%14)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N%17[C@@H](CCC%17)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CNC(CCCCCCCCCCCCC)=O
Biological Activity: Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bulevirtide | 99.70% | Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442. [Content Brief]
- [2]. Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858. [Content Brief]
Keywords
